iTrack™ is the only illuminated, micron-scale microcatheter designed to viscodilate Schlemm’s canal during MIGS with ABiC™. A standout feature of the iTrack™ is its illuminated tip, which allows you to continually monitor its location during canal circumnavigation.

ABiC WITH iTRACK

SCHEDULE A DEMO

Performed as a standalone procedure or as an adjunct to cataract surgery, ABiC is a new MIGS procedure that can comprehensively restore the natural outflow pathway in glaucoma patients.

Introducing a new comprenhensive MIGS

LEARN MORE

Vitreolysis. Redefining Convention.

Virtually every individual will experience the visual shadows caused by vitreous strands and opacities during their lifetime. Vitreolysis provides an effective outpatient-based treatment for floaters and overcomes many of the risks associated with traditional surgery.

LEARN MORE

SLT. Gentle. Effective Repeatable.

A highly effective approach for first-line glaucoma treatments, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail, Selective Laser Trabeculoplasty (SLT) stimulates a natural healing response in the eye to manage intraocular pressure.

LEARN MORE

2RT® is a nanosecond laser therapy that stimulates a natural, biological healing response in the eye to treat degenerative retinal disease, including AMD.

For 30 years, Ellex has been at the forefront of ophthalmic innovation, introducing cutting-edge products and technologies for the diagnosis and treatment of eye disease.

Pioneering solutions for eye care since 1985.

For more than 30 years, Ellex has been committed to the fight against blindness. Our vision is to pioneer integrated medical technologies and solutions for the diagnosis and treatment of eye disease.

A Global Outlook.

Over the years, Ellex has evolved from a small scientific laser company to a global leader in medical technologies. Today, more than 30,000 Ellex laser and ultrasound systems are used around the world in the fight against blindness.

12 April 2010

Ellex Secures Sublicense Agreement for Ellex 2RT

Adelaide, Australia, 12 April 2010: Ellex Medical Lasers Limited (ASX: ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced that it has sublicensed Patent No. 5,549,596, effectively enabling the Company to bring Ellex 2RT™ technology to market in the US.

Under the terms of the agreement, Ellex has been granted non-exclusive rights to the retinal aspects of Patent No. 5,549,596 (“Selective Laser Targeting of Pigmented Ocular Cells”), which is held by a leading medical laser research institute in the US.

Previously, Ellex had been prevented from entering the US market with Ellex 2RT™ due to Patent No. 5,549,596; however, with the sublicense agreement now in place Ellex customers in the US will be able to use Ellex 2RT™ for the treatment of retinal disease.

The Intellectual Property (IP) pathway for Ellex 2RT™ is unencumbered outside of the US, and the Company has filed for four international patents related to the Ellex 2RT™ Program.

Ellex CEO, Mr. Simon Luscombe, said that the sublicense agreement was a major milestone, allowing the Company to proceed with a definitive plan to launch Ellex 2RT™ in the US market.

“The next phase of the Ellex 2RT™ Program will focus on undertaking further clinical trials, and on obtaining key regulatory approvals for the Ellex 2RT™ product range”, commented Mr. Luscombe.

Ellex 2RT™ is a non-damaging laser treatment that stimulates regeneration of the retinal pigment epithelium (RPE) to preserve vision, and aims to treat the RPE before vision loss occurs — offering a breakthrough treatment option for a range of degenerative diseases that ultimately result in blindness. Early clinical trials have been conducted at St. Thomas&rsqup; Hospital in London, with further clinical trials currently underway in Australia to validate the efficacy of Ellex 2RT™ for a number of clinical indications.

If successful, Ellex 2RT™ has the potential to significantly improve the quality of life of millions of elderly people and to reduce health care expenditure worldwide.

“Since launching the Ellex 2RT™ Program we have made significant progress, and the sublicense agreement marks an important next step. We are committed to advancing the role of laser technology in ophthalmology, and look forward to pursuing the opportunities to bring this revolutionary technology to market.”

ABOUT ELLEX

Ellex Medical Lasers Limited (ASX:ELX) designs, manufactures and markets a complete line of lasers and diagnostic ultrasound systems used by ophthalmologists to diagnose and treat eye disease. With more than 14,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, Germany and Australia, and a network of distribution partners in more than 100 countries. In December 2006 Ellex acquired Innovative Imaging, a leading provider of diagnostic ultrasound systems for ophthalmology, initiating the expansion of our product line beyond lasers.

The Ellex name has long been synonymous with excellence in technology, in quality, and in customer care. Ellex maintains the highest quality standards through product development and manufacturing, and strives to provide unmatched levels of clinical expertise and support to our customers. All of these efforts have combined to produce one of the highest levels of customer satisfaction in the ophthalmic industry.